Evidence map›Paper›PMID 34638595›Full record

ReviewInternational journal of molecular sciences2021

Human iPSC-Derived Glia as a Tool for Neuropsychiatric Research and Drug Development.

Johanna Heider, Sabrina Vogel, Hansjürgen Volkmer, Ricarda Breitmeyer

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Microglia-neuron interactions in schizophrenia.Frontiers in cellular neuroscience · 2024
    Review
  11. The Janus face of antipsychotics in glial cells: Focus on glioprotection.Experimental biology and medicine (Maywood, N.J.) · 2023
    Review
  12. hiPSC-Derived Cells as Models for Drug Discovery 2.0.International journal of molecular sciences · 2023
    Article
  13. Review
  14. Vesicular Glutamate Release from Feeder-FreehiPSC-Derived Neurons.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Johanna HeiderMolecular Neurobiology, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Sabrina VogelMolecular Neurobiology, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Hansjürgen VolkmerMolecular Neurobiology, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Ricarda BreitmeyerMolecular Neurobiology, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.ORCID 0000-0003-4796-1231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropsychiatric disorders such as schizophrenia or autism spectrum disorder represent a leading and growing burden on worldwide mental health. Fundamental lack in understanding the underlying pathobiology compromises efficient drug development despite the immense medical need. So far, antipsychotic drugs reduce symptom severity and enhance quality of life, but there is no cure available. On the molecular level, schizophrenia and autism spectrum disorders correlate with compromised neuronal phenotypes. There is increasing evidence that aberrant neuroinflammatory responses of glial cells account for synaptic pathologies through deregulated communication and reciprocal modulation. Consequently, microglia and astrocytes emerge as central targets for anti-inflammatory treatment to preserve organization and homeostasis of the central nervous system. Studying the impact of neuroinflammation in the context of neuropsychiatric disorders is, however, limited by the lack of relevant human cellular test systems that are able to represent the dynamic cellular processes and molecular changes observed in human tissue. Today, patient-derived induced pluripotent stem cells offer the opportunity to study neuroinflammatory mechanisms in vitro that comprise the genetic background of affected patients. In this review, we summarize the major findings of iPSC-based microglia and astrocyte research in the context of neuropsychiatric diseases and highlight the benefit of 2D and 3D co-culture models for the generation of efficient in vitro models for target screening and drug development.

Indexed as

AnimalsAstrocytesCentral Nervous SystemDrug DevelopmentHumansInduced Pluripotent Stem CellsInflammationMental DisordersMicrogliaNeurogliaNeuronsQuality of Lifeastrocytesautism spectrum disorderCNSinflammationiPSCmicroglianeuropsychiatric diseasesschizophrenia

Identifiers

PMID34638595
PMCPMC8508580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.